Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Guardant Health

Biotech & Life Sciences · Palo Alto, United States · Founded 2012 · IPO 2018 Decacorn

Improving patient health through technology breakthroughs in oncology.

Valuation
$12B
Market cap · May/2026
Revenue
$981M
Latest reported FY

Investors

20 investors on Guardant Health's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Osage University Partners
frank malek
Sequoia
Farzad (Zod) Nazem

Global footprint

Where Guardant Health has talent and traffic

AI talent share
0.4% of workforce is AI talent
(18 of 4,475 staff)
Core AI60.13%
Other AI120.27%
Non-AI workforce4,45799.6%
Workforce by country
🇺🇸 United States · Palo Alto HQ
Book a demo for the full country breakdown
Web traffic by country
85K monthly visits
across markets
🇺🇸 United States65.3%
🇬🇧 United Kingdom12.4%
🇨🇦 Canada2.9%
🇮🇳 India2.8%
🇸🇬 Singapore2.6%
Top 5 markets shown

Patent intelligence

$97M patent portfolio · 163 active families

Estimated portfolio value
$97M
0.81% of market cap · 28.1× smaller than top peer Illumina ($2.7B)
163 active patent families
Where Guardant Health innovates BioinformaticsCellComputational biologyMolecular biologyMethylation

Where Guardant Health concentrates vs peers

Each axis is a top-10 topic across Guardant Health and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Guardant Health's 2 investments and acquisitions.

Every disclosed deal where Guardant Health appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Guardant Health's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Guardant Health deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Guardant Health's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Guardant Health

        An AI-synthesized read of the highest-engagement posts about Guardant Health on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Guardant Health on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.